Exane Derivatives’s QTS REALTY TRUST, INC. QTS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-281
| Closed | -$21.8K | – | 1092 |
|
|
2021
Q2 | $21.8K | Buy |
281
+280
| +28,000% | +$19K | ﹤0.01% | 697 |
|
|
2021
Q1 | $62 | Hold |
1
| – | – | ﹤0.01% | 864 |
|
|
2020
Q4 | $62 | Hold |
1
| – | – | ﹤0.01% | 808 |
|
|
2020
Q3 | $63 | Hold |
1
| – | – | ﹤0.01% | 735 |
|
|
2020
Q2 | $64 | Hold |
1
| – | – | ﹤0.01% | 672 |
|
|
2020
Q1 | $58 | Hold |
1
| – | – | ﹤0.01% | 681 |
|
|
2019
Q4 | $53 | Hold |
1
| – | – | ﹤0.01% | 664 |
|
|
2019
Q3 | $51 | Hold |
1
| – | – | ﹤0.01% | 641 |
|
|
2019
Q2 | $46 | Hold |
1
| – | – | ﹤0.01% | 651 |
|
|
2019
Q1 | $45 | Hold |
1
| – | – | ﹤0.01% | 600 |
|
|
2018
Q4 | $37 | Hold |
1
| – | – | ﹤0.01% | 655 |
|
|
2018
Q3 | $42 | Hold |
1
| – | – | ﹤0.01% | 650 |
|
|
2018
Q2 | $39 | Hold |
1
| – | – | ﹤0.01% | 645 |
|
|
2018
Q1 | $35 | Hold |
1
| – | – | ﹤0.01% | 585 |
|
|
2017
Q4 | $54 | Hold |
1
| – | – | ﹤0.01% | 563 |
|
|
2017
Q3 | $52 | Buy |
+1
| New | +$53 | ﹤0.01% | 534 |
|
Exane Derivatives's QTS Position: Q3 2021 in Review
Exane Derivatives sold out of QTS REALTY TRUST, INC. (QTS) in Q3 2021, closing a stake of 281 shares — an estimated $21.8K sold.
Exane Derivatives first reported a position in QTS in Q3 2017 and held it in 16 quarters. The position peaked at $21.8K in Q2 2021. 0 funds tracked by Wall St. Rank hold QTS as of Q3 2021.
- Exane Derivatives reported no remaining QTS REALTY TRUST, INC. position as of Q3 2021 after selling out during the quarter.
- Exane Derivatives sold 281 QTS REALTY TRUST, INC. shares in Q3 2021, an estimated $21.8K.
- Exane Derivatives first reported a position in QTS REALTY TRUST, INC. in Q3 2017 and held it in 16 quarters.
- Exane Derivatives's QTS REALTY TRUST, INC. position peaked at $21.8K in Q2 2021.
- 0 funds tracked by Wall St. Rank held QTS REALTY TRUST, INC. as of Q3 2021.
Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.